Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
PubMed
29423615
DOI
10.1007/s00415-018-8759-1
PII: 10.1007/s00415-018-8759-1
Knihovny.cz E-zdroje
- Klíčová slova
- Botulinum toxin therapy, Contractures, Dystonia, Rigidity, Spasms, Spasticity, Treatment,
- MeSH
- botulotoxiny terapeutické užití MeSH
- lidé MeSH
- neurotoxiny terapeutické užití MeSH
- pohybové poruchy farmakoterapie MeSH
- svalová spasticita diagnóza farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- botulotoxiny MeSH
- neurotoxiny MeSH
Spasticity is a symptom occurring in many neurological conditions including stroke, multiple sclerosis, hypoxic brain damage, traumatic brain injury, tumours and heredodegenerative diseases. It affects large numbers of patients and may cause major disability. So far, spasticity has merely been described as part of the upper motor neurone syndrome or defined in a narrowed neurophysiological sense. This consensus organised by IAB-Interdisciplinary Working Group Movement Disorders wants to provide a brief and practical new definition of spasticity-for the first time-based on its various forms of muscle hyperactivity as described in the current movement disorders terminology. We propose the following new definition system: Spasticity describes involuntary muscle hyperactivity in the presence of central paresis. The involuntary muscle hyperactivity can consist of various forms of muscle hyperactivity: spasticity sensu strictu describes involuntary muscle hyperactivity triggered by rapid passive joint movements, rigidity involuntary muscle hyperactivity triggered by slow passive joint movements, dystonia spontaneous involuntary muscle hyperactivity and spasms complex involuntary movements usually triggered by sensory or acoustic stimuli. Spasticity can be described by a documentation system grouped along clinical picture (axis 1), aetiology (axis 2), localisation (axis 3) and additional central nervous system deficits (axis 4). Our new definition allows distinction of spasticity components accessible to BT therapy and those inaccessible. The documentation sheet presented provides essential information for planning of BT therapy.
Azienda Ospedaliera Santa Maria di Terni Terni Italy
Centre de Rééducation et Medicine Physique Hôpital du Jura Porrentruy Switzerland
Clinic 'Cecil Plus' Moscow Russia
Department of Neurology King Faisal Specialist Hospital Riyyad Kingdom of Saudi Arabia
Department of Neurology Ljubljana University Medical Centre Ljubljana Slovenia
Department of Neurology Palacky University Olomouc Czech Republic
Department of Neurology Rheinische Friedrich Wilhelms Universität Bonn Germany
Department of Neurology Rostock University Rostock Germany
Department of Neurology University of Monterrey Monterrey Nueva Leon Mexico
Department of Neurology University of Santiago de Chile Santiago de Chile Chile
Department of Neurology University of Santo Tomas Hospital Manila Philippines
Department of Neurology University of Sao Paulo Sao Paulo Brazil
Department of Neurology University of Tokushima Tokushima Japan
Department of Neurology University of Zagreb Zagreb Croatia
Gailtal Klinik Hermagor Austria
Helios Klinik Leezen Leezen Germany
IAB Interdisciplinary Working Group for Movement Disorders Hamburg Germany
Maternus Klinik für Rehabilitation Bad Oeynhausen Germany
Zobrazit více v PubMed
Curr Opin Microbiol. 2012 Jun;15(3):325-36 PubMed
Drugs. 2017 Apr;77(5):563-574 PubMed
Neuropsychiatr Dis Treat. 2016 Jan 27;12:251-63 PubMed
J Neurol Sci. 1965 Jan-Feb;2(1):7-29 PubMed
Muscle Nerve. 2018 Feb;57(2):245-254 PubMed
J Pediatr Neurosci. 2011 Oct;6(Suppl 1):S118-25 PubMed
Neurology. 2017 Apr 4;88(14 ):1321-1328 PubMed
BMC Neurol. 2013 Sep 08;13:118 PubMed
Int J Gen Med. 2013;6:135-44 PubMed
J Neurol Sci. 2000 Apr 15;175(2):145-55 PubMed
Ann Neurol. 1990 Oct;28(4):512-5 PubMed
J Neural Transm (Vienna). 2015 Nov;122(11):1573-9 PubMed
J Neural Transm (Vienna). 2015 Feb;122(2):327-33 PubMed
Expert Rev Neurother. 2003 Nov;3(6):773-85 PubMed